Mutlu Hizal
Overview
Explore the profile of Mutlu Hizal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Large Unstained Cells: A Predictive Biomarker for Recurrence and Survival in Resected Gastric Cancer
Ceylan F, Tenekeci A, Bilgin B, Sendur M, Hizal M, Kos F, et al.
Medicina (Kaunas)
. 2025 Feb;
61(2).
PMID: 40005326
Despite advances in surgery and perioperative chemotherapy, locally advanced gastric cancer continues to pose significant challenges, creating a pressing need for biomarkers capable of predicting therapeutic efficacy and survival outcomes....
2.
Kahraman S, Hizal M, Demirel B, Guven D, Gumusay O, Uluc B, et al.
BMC Cancer
. 2024 Dec;
24(1):1592.
PMID: 39736618
Highly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2-...
3.
Hizal M, Tufan A, Mercan R, Pasaoglu O, Pasaoglu H, Haznedaroglu S, et al.
Sci Rep
. 2024 Sep;
14(1):21351.
PMID: 39266694
In a previous study, it has been shown that the population of Th17 lymphocytes was increased in patients with FMF. IL-21 and IL-23 play significant roles in the production and...
4.
Erbahceci Timur I, Acikgoz V, Ugurlu N, Yalcin B, Sendur M, Hizal M, et al.
Cutan Ocul Toxicol
. 2023 Jun;
42(3):109-117.
PMID: 37272809
Purpose: To evaluate the vascular structure of the choroid and each retinal layer in patients with breast cancer on tamoxifen therapy and compare them with healthy subjects. Materials And Methods:...
5.
Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel B, et al.
Future Oncol
. 2023 May;
19(10):727-736.
PMID: 37133230
Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The authors report retrospective...
6.
Kahraman S, Bardakci M, Aykan M, Yasar S, Erol C, Hizal M, et al.
J Cancer Res Ther
. 2023 Apr;
19(2):347-354.
PMID: 37006071
Objective: Neuroendocrine neoplasms (NENs) originate from the diffuse neuroendocrine cell system and constitute a heterogeneous group of tumors exhibiting diverse clinical and biological characteristics. NENs include well-differentiated neuroendocrine tumors (NETs)...
7.
Erol C, Sendur M, Bilgetekin I, Garbioglu D, Hamdard J, Akbas S, et al.
J Cancer Res Ther
. 2022 Dec;
18(12 Suppl 2):S347-S353.
PMID: 36510987
Aims: The addition of aflibercept to the fluorouracil and irinotecan (FOLFIRI) regimen significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) previously treated with oxaliplatin. We aimed to...
8.
Erol C, Sakin A, Basoglu T, Ozden E, Cabuk D, Dogan M, et al.
Turk J Med Sci
. 2022 Nov;
52(4):1022-1032.
PMID: 36326360
Background: Perioperative FLOT regimen is a standard of care in locally advanced operable gastric and GEJ adenocarcinoma. We aimed to determine the efficacy, prognostic factors of perioperative FLOT chemotherapy in...
9.
Akyol P, Dede D, Bilgin B, Ulas A, Sendur M, Akinci M, et al.
J Cancer Res Ther
. 2022 Sep;
18(4):1114-1118.
PMID: 36149169
Aim: Thiols are the organic compounds of the antioxidant system. There is limited data in the literature concerning chemotherapy (CT) in cancer and thiol balance. In this study, we aimed...
10.
Hizal M, Bilgin B, Paksoy N, Atci M, Kahraman S, Kilickap S, et al.
J Cancer Res Clin Oncol
. 2022 Sep;
149(8):4141-4148.
PMID: 36048274
Introduction: Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced ALK-positive NSCLC. Recent studies demonstrated that the percentage of ALK-positive...